ChipsThe Motley Foolabout 19 hours ago
AbbVie's New Blood Cancer Data Supports Dividend Growth
1 min read
AbbVie presented 21 new clinical data sets at the European Hematology Association Congress covering multiple blood cancers. The company's oncology portfolio generated $6.7 billion in 2025 revenue. Strong clinical results support future cash flow, which underpins AbbVie's dividend yield above 3%.
Level
Hype check
Tap to vote and see what everyone thinks.
